GILEAD AND GALAPAGOS TO PRESENT NEW DATA ON FILGOTINIB AT 2019 ACR/ARP ANNUAL MEETING

NEXT STORY
Paratek Announces Top Line Results of Phase 2 Clinical Studies of Omadacycline in Urinary Tract Infections
PREV STORY
Cytokinetics Reports Third Quarter 2019 Financial Results
Subscribe to PM360
Follow Us

Experts on Call

Get in touch with PM360 Experts On Call

Ads

You May Also Like

Vascepa® (icosapent ethyl) 26% Reduction in Key Secondary Composite Endpoint of Cardiovascular Death, Heart Attacks and Stroke Demonstrated in REDUCE-IT™ Supports 25% Overall Reduction in Five-Point Major Adverse Cardiovascular Event Primary Composite Endpoint

Landmark Cardiovascular Risk Reduction Benefits Demonstrated in REDUCE-IT Are Largest of Any Major Cardiovascular ...

author_avatar
NASDAQ Market News

Recro Pharma Announces Publication of Phase II IV Meloxicam Abdominal Hysterectomy Data in Anesthesia & Analgesia

MALVERN, Pa., Nov. 14, 2018 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (NASDAQ:REPH), a revenue ...

author_avatar
NASDAQ Market News

Merus to Present at the 2017 Wedbush PacGrow Healthcare Conference

UTRECHT, The Netherlands, Aug. 09, 2017 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage ...

author_avatar
NASDAQ Market News